company

History

Rophibio History

Established in 2015, Rophibio strives to create Biosimilars, Biopharmaceutical, and Innovative drugs.

2024 ~
2024.01
RBS-001(Eylea BS) EU CTA
2024.03
RBS-001 (Eylea BS) US FDA IND Submssion
2021 ~ 2023
2023.11
RBS-001(Eylea BS) MFDS IND application
2023.09
CEO Stanley SeungSuh Hong appointed as sole CEO
2023.08
Secured investment from Amicogen and Bifido
2023.04
Dr. Stanley SeungSuh Hong appointed as CEO
2022.12
Secured investment from Amicogen and Bifido
2022.11
Signed MOU with C&R Research (CRO) for RBS-001
2021.11
Secured investment from Amicogen and Bifido Research collaboration agreement with Cheongju University and Chungbuk Bioindustry-University Cooperation Institute
2021.05
Student training with Cheongju University
2018 ~ 2020
2020.05
Secured investment from Myungsung Lifix Research, and received grant by KITIA (Korea Core Industrial Technology Investment Association)
2019.08
IP grant by KIPO (Korean Intellectual Property Office)
2019.02
Research grant by MOTIE (Ministry of Trade, Industry and Energy)
2018.11
Headquarters relocate to SB Plaza
2018.01
SME accreditation
2015 ~ 2017
2017. 12
LMO laboratory accreditation
2016. 01
Research grant by Osong Medical Innovation
2015. 04
Certified as a venture company
2015. 02
Established Rophibio, Inc.